News Releases

News releases related to ophthalmology

2023

8 SEP 2023

Pharmaceuticals

Otsuka collaborates with Shape^TX to develop novel AAV gene therapies for ocular diseases

2020

16 JUN 2020

Pharmaceuticals

Launch of a New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE^® Combination Ophthalmic Suspension

2019

9 DEC 2019

Pharmaceuticals

Senju and Otsuka Launch a New Treatment for Glaucoma and Ocular Hypertension - AIBETA^® Combination Ophthalmic Solution

2017

3 MAR 2017

Pharmaceuticals

Otsuka Supports "Light-Up in Green" Glaucoma Awareness Activities

11 JAN 2017

Pharmaceuticals

Otsuka Launches a New Treatment for Glaucoma and Ocular Hypertension - Mikeluna^® Combination Ophthalmic Solution in Japan

2016

28 SEP 2016

Pharmaceuticals

Otsuka Receives Approval in Japan for Mikeluna^® Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension

14 SEP 2016

Pharmaceuticals

Announcement of Co-promotion of New Glaucoma Treatment (PDF: 45.7 KB)

14 JUN 2016

Pharmaceuticals

Announcement of Termination of Co-Development and Co-Commercialization Agreements with Acucela, Inc.

2015

1 OCT 2015

Pharmaceuticals

New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension

2013

9 MAY 2013

Pharmaceuticals

Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting

2012

19 JUL 2012

Pharmaceuticals

Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients with Dry Eye Syndrome

5 JAN 2012

Pharmaceuticals

Mucosta^® ophthalmic suspension UD2% releases on January 5, 2012

2011

6 MAY 2011

Pharmaceuticals

Phase III Study Results for Rebamipide Ophthalmic Suspension for Dry Eye Announced at ARVO 2011

2010

9 NOV 2010

Pharmaceuticals

Otsuka Pharmaceutical Files for Regulatory Approval in Japan for Mucosta^® Ophthalmic Suspension for Dry Eye

27 SEP 2010

Pharmaceuticals

Otsuka Pharmaceutical and Acucela Enter New Co-Development and Co-Promotion Agreement for OPA-6566 for Glaucoma

17 MAR 2010

Pharmaceuticals

Otsuka Pharmaceutical and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD Novel, Oral Therapy in Phase 2 Clinical Trial for Dry AMD, A Leading Cause of Blindness in People Over Age 50

2008

4 SEP 2008

Pharmaceuticals

Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration

4 SEP 2008

Pharmaceuticals

News releases related to ophthalmology

Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases

Launch of a New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE® Combination Ophthalmic Suspension

Senju and Otsuka Launch a New Treatment for Glaucoma and Ocular Hypertension - AIBETA® Combination Ophthalmic Solution

Otsuka Supports "Light-Up in Green" Glaucoma Awareness Activities

Otsuka Launches a New Treatment for Glaucoma and Ocular Hypertension - Mikeluna® Combination Ophthalmic Solution in Japan

Otsuka Receives Approval in Japan for Mikeluna® Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension

Announcement of Co-promotion of New Glaucoma Treatment (PDF: 45.7 KB)

Announcement of Termination of Co-Development and Co-Commercialization Agreements with Acucela, Inc.

New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension

Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting

Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients with Dry Eye Syndrome

Mucosta® ophthalmic suspension UD2% releases on January 5, 2012

Phase III Study Results for Rebamipide Ophthalmic Suspension for Dry Eye Announced at ARVO 2011

Otsuka Pharmaceutical Files for Regulatory Approval in Japan for Mucosta® Ophthalmic Suspension for Dry Eye

Otsuka Pharmaceutical and Acucela Enter New Co-Development and Co-Promotion Agreement for OPA-6566 for Glaucoma

Otsuka Pharmaceutical and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD Novel, Oral Therapy in Phase 2 Clinical Trial for Dry AMD, A Leading Cause of Blindness in People Over Age 50

Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration

Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry Eye

Otsuka collaborates with Shape^TX to develop novel AAV gene therapies for ocular diseases

Launch of a New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE^® Combination Ophthalmic Suspension

Senju and Otsuka Launch a New Treatment for Glaucoma and Ocular Hypertension - AIBETA^® Combination Ophthalmic Solution

Otsuka Launches a New Treatment for Glaucoma and Ocular Hypertension - Mikeluna^® Combination Ophthalmic Solution in Japan

Otsuka Receives Approval in Japan for Mikeluna^® Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension

Mucosta^® ophthalmic suspension UD2% releases on January 5, 2012

Otsuka Pharmaceutical Files for Regulatory Approval in Japan for Mucosta^® Ophthalmic Suspension for Dry Eye